ABSTRACT Purpose: Minimally invasive radical nephrectomy is often preferred for larger renal tumours not suitable for partial nephrectomy (1). When performed with a multiport robot, the procedure is routinely performed with a transperitoneal approach, with recent studies highlighting important factors for surgical outcomes, including predictive factors (2), segmental artery unclamping techniques (3), and comparisons of robotic techniques (4). This video shows that SP Robot-Assisted Radical Nephrectomy (RARN) via a lower anterior approach is valuable in challenging cases. Materials and Methods: We performed SP-RARN on two complex patients using a retroperitoneal lower anterior approach. The first patient, a 54-year-old female with a BMI of 36.8 kg/m2, had a ventral hernia and bowel obstruction history, with a 9 cm right middle kidney mass. The second patient, a 58-year-old male with a BMI of 31.19 kg/m2, had ESRD and was on peritoneal dialysis for 8 years, with a 3.4x3.7 cm mass in the right superior pole, suspected to be RCC. The surgical technique is detailed in the video. Results: Both procedures were successful, with operative times of 173 and 203 minutes and blood loss of 150 mL. No complications occurred. Patients were discharged after 31 and 38 hours, respectively. Histopathology confirmed RCC. At the 3-month follow-up, no complications or readmissions were reported. Second patient continued peritoneal dialysis without issues. Conclusion: Retroperitoneal SP-RARN via the lower anterior approach avoids the peritoneal cavity, making it suitable for certain patients. In these patients, more so than in others, this procedure is feasible, safe, and less morbid than the standard multiport approach. Purpose 1. 1 . (1) robot outcomes 2, 2 , (2) 3, 3 (3) 4. 4 (4) RobotAssisted Robot Assisted RARN (RARN cases Methods SPRARN 54yearold yearold 54 year old 368 36 36. kgm2 kgm kg m2 m kg/m2 history 58yearold 58 3119 19 31.1 years 34x37 x 4x3 7 3.4x3. pole RCC Results successful 17 20 15 mL occurred hours respectively 3month month followup, followup follow up, up follow-up reported issues Conclusion cavity others feasible safe (1 (2 (3 (4 5 kg/m 311 31. 34x3 4x 3.4x3 ( 34x 3.4x

ABSTRACT Introduction: Endoscopic Combined Intrarenal Surgery (ECIRS) has emerged as a promising technique for the management of large and complex kidney stones, potentially offering advantages over traditional Percutaneous Nephrolithotomy (PCNL). This study aims to evaluate best practices, outcomes, and future perspectives associated with ECIRS. Materials and Methods: A comprehensive PubMed search was conducted from 2008 to 2024, using MESH terms and the following key words: "ECIRS" and "Endoscopic Combined Intrarenal Surgery" The search yielded 157 articles, including retrospective cohort studies, two randomized controlled trials (RCTs), and four meta-analyses comparing ECIRS with PCNL. Most important findings were summarized regarding indications, patient positioning, kidney access, tract size, surgical outcomes, and complications. Results: ECIRS demonstrated higher stone-free rate, lower complication rate, and a reduced need for multiple procedures compared to traditional PCNL. Additionally, ECIRS has the potential to integrate new technologies to further enhance outcomes. Conclusion: ECIRS demonstrates significant advantages in the management of large kidney stones. Future research should focus on well-designed RCTs to provide robust evidence of its efficacy, safety, and cost-effectiveness, potentially establishing ECIRS as the first option treatment for complex kidney stones. Introduction (ECIRS stones PCNL . (PCNL) practices outcomes Methods 200 2024 words "ECIRS 15 articles studies RCTs, , (RCTs) metaanalyses meta analyses indications positioning access size complications Results stonefree stone free rate Additionally Conclusion welldesigned well designed efficacy safety costeffectiveness, costeffectiveness cost effectiveness, effectiveness cost-effectiveness (PCNL 20 202 1 (RCTs 2

Abstract Background: Urinary tract infections (UTIs) are the second most common cause of graft dysfunction, accounting for significant morbidity, and are associated with poor graft and patient survival. This study aimed to assess the association between post-renal transplant UTI and graft outcomes. Methods: We examined the effect of UTIs on graft outcomes in patients who underwent renal transplantation surgery between January 2010 and December 2022. The study population included 349 renal transplantations, of which 74 experienced 140 UTI events. Based on the number of UTI episodes, patients were categorized into three groups. Results: Of the 349 recipients, 275 (74.4%) had no UTI, 47 (18.8%) had non-recurrent UTIs (NR-UTIs), and 27 (6.8%) had recurrent UTIs (R-UTIs). Kaplan-Meier survival analysis showed that post-KT UTI status was a significant factor in graft survival, death-censored graft survival, and patient survival after a follow up of 5 years (log rank, P < 0.001). R-UTIs were associated with very poor graft survival and patient survival when compared with no UTI after a follow up of 5 years (hazard ratio [HR], 1.506; 95% confidence interval [CI], 1.233–1.840; P < 0.001 & HR, 1.529; 95% CI, 1.227–1.905; P = 0.001). R-UTIs were more likely to be associated with multi-drug resistant Gram-negative organisms (Klebsiella pneumonia or Escherichia coli) with resistance to nitrofurantoin (RR, 2.753; 95% CI, 1.257–6.032; P = 0.01) and carbapenem (RR, 2.064; 95% CI, 0.988–4.314; P = 0.05). Conclusion: Compared to no UTI, R-UTIs were associated to worse graft and patient outcomes after a follow-up of 5 years, whereas NR-UTIs were associated with poor graft and patient outcomes in the long term. Background (UTIs dysfunction morbidity postrenal post Methods 201 2022 34 transplantations 7 14 events episodes groups Results recipients 74.4% 744 4 (74.4% 18.8% 188 18 8 (18.8% nonrecurrent non NRUTIs, NRUTIs NR , (NR-UTIs) 2 6.8% 68 6 (6.8% RUTIs. RUTIs R . (R-UTIs) KaplanMeier Kaplan Meier postKT KT deathcensored death censored log rank 0.001. 0001 0 001 0.001) hazard HR [HR] 1.506 1506 1 506 95 CI [CI] 1.233–1.840 12331840 233 840 0.00 1.529 1529 529 1.227–1.905 12271905 227 905 multidrug multi drug Gramnegative Gram negative Klebsiella coli RR, RR (RR 2.753 2753 753 1.257–6.032 12576032 257 032 0.01 01 2.064 2064 064 0.988–4.314 09884314 988 314 0.05. 005 0.05 05 0.05) Conclusion followup term 20 202 3 74.4 (74.4 18.8 (18.8 (NR-UTIs 6.8 (6.8 (R-UTIs 000 00 [HR 1.50 150 50 9 [CI 1.233–1.84 1233184 23 84 0.0 1.52 152 52 1.227–1.90 1227190 22 90 2.75 75 1.257–6.03 1257603 25 03 2.06 206 06 0.988–4.31 0988431 98 31 74. (74. 18. (18. 6. (6. 1.5 15 1.233–1.8 123318 0. 1.227–1.9 122719 2.7 1.257–6.0 125760 2.0 0.988–4.3 098843 (74 (18 (6 1. 1.233–1. 12331 1.227–1. 12271 2. 1.257–6. 12576 0.988–4. 09884 (7 (1 ( 1.233–1 1233 1.227–1 1227 1.257–6 1257 0.988–4 0988 1.233– 123 1.227– 122 1.257– 125 0.988– 098 1.233 12 1.227 1.257 0.988 09 1.23 1.22 1.25 0.98 1.2 0.9

Resumo Histórico: Infecções do trato urinário (ITU) são a segunda causa mais comum de disfunção do enxerto, responsáveis por morbidade significativa, sendo associadas à baixa sobrevida do enxerto e paciente. O objetivo deste estudo foi avaliar associação entre ITU pós-transplante renal e desfechos do enxerto. Métodos: Examinamos o efeito das ITU nos desfechos do enxerto em pacientes submetidos ao transplante renal entre janeiro/2010 e dezembro/2022. A população do estudo incluiu 349 transplantes renais, dos quais 74 apresentaram 140 eventos de ITU. Baseado no número de episódios de ITU, categorizamos os pacientes em três grupos. Resultados: Dos 349 receptores, 275 (74,4%) não apresentaram ITU, 47 (18,8%) apresentaram ITU não recorrentes (ITU-NR) e 27 (6,8%) apresentaram ITU recorrentes (ITU-R). O método de Kaplan-Meier mostrou que o status da ITU pós-TR foi um fator significativo na sobrevida do enxerto, sobrevida do enxerto censurada para óbito e sobrevida do paciente após acompanhamento de 5 anos (log rank, P < 0,001). ITU-R foram associadas à sobrevida muito baixa do enxerto e sobrevida do paciente comparadas com nenhuma ITU após acompanhamento de 5 anos (razão de risco [RR], 1,506; IC 95%, 1,233–1,840; P < 0,001 & RR, 1,529; IC 95%, 1,227–1,905; P = 0,001). ITU-R apresentaram maior probabilidade de serem associadas a organismos Gram-negativos multirresistentes (Klebsiella pneumonia ou Escherichia coli) resistentes à nitrofurantoína (RR, 2,753; IC 95%, 1,257–6,032; P = 0,01) e carbapenem (RR, 2,064; IC 95%, 0,988–4,314; P = 0,05). Conclusão: Em comparação com ausência de ITU, ITU-R foram associadas a piores desfechos do enxerto e paciente após acompanhamento de 5 anos, enquanto ITU-NR foram associadas a piores desfechos do enxerto e paciente em longo prazo. Histórico (ITU significativa póstransplante pós Métodos janeiro2010 janeiro 2010 janeiro/201 dezembro2022 dezembro 2022 dezembro/2022 34 renais 7 14 grupos Resultados receptores 74,4% 744 4 (74,4% 18,8% 188 18 8 (18,8% ITUNR NR (ITU-NR 2 6,8% 68 6 (6,8% ITUR. ITUR R . (ITU-R) KaplanMeier Kaplan Meier pósTR TR log rank 0,001. 0001 0 001 0,001) razão RR , [RR] 1,506 1506 1 506 95 95% 1,233–1,840 12331840 233 840 0,00 1,529 1529 529 1,227–1,905 12271905 227 905 Gramnegativos Gram negativos Klebsiella coli (RR 2,753 2753 753 1,257–6,032 12576032 257 032 0,01 01 2,064 2064 064 0,988–4,314 09884314 988 314 0,05. 005 0,05 05 0,05) Conclusão prazo janeiro201 201 janeiro/20 dezembro202 202 dezembro/202 3 74,4 (74,4 18,8 (18,8 6,8 (6,8 (ITU-R 000 00 [RR 1,50 150 50 9 1,233–1,84 1233184 23 84 0,0 1,52 152 52 1,227–1,90 1227190 22 90 2,75 75 1,257–6,03 1257603 25 03 2,06 206 06 0,988–4,31 0988431 98 31 janeiro20 20 janeiro/2 dezembro20 dezembro/20 74, (74, 18, (18, 6, (6, 1,5 15 1,233–1,8 123318 0, 1,227–1,9 122719 2,7 1,257–6,0 125760 2,0 0,988–4,3 098843 janeiro2 janeiro/ dezembro2 dezembro/2 (74 (18 (6 1, 1,233–1, 12331 1,227–1, 12271 2, 1,257–6, 12576 0,988–4, 09884 dezembro/ (7 (1 ( 1,233–1 1233 1,227–1 1227 1,257–6 1257 0,988–4 0988 1,233– 123 1,227– 122 1,257– 125 0,988– 098 1,233 12 1,227 1,257 0,988 09 1,23 1,22 1,25 0,98 1,2 0,9

Abstract Introduction: This study investigated variables associated with mortality in kidney transplant recipients (KTRs) diagnosed with post-transplant lymphoproliferative disease (PTLD) and a simultaneous Epstein-Barr virus (EBV) viremia. Methods: This was a retrospective cohort study enrolling KTRs diagnosed with PTLD between 2018 and 2020. Outcome: death within two years after diagnosis. Results: Among 1,625 KTRs who collected EBV viremia (by PCR, 2018–2020) for any reason, 238 (14.6%) had a positive viral load and 41 (17.2%) simultaneous PTLD. These 41 patients were 40.1 years old at diagnosis and 8.6 years after transplantation; 26.8% were induced with rATG and 92.7% were maintained on tacrolimus and azathioprine (TAC/AZA) as immunosuppressive regimen. Lymph nodes (75.6%) was the most common site of PTLD, followed by the gastrointestinal tract (48.8%), with 61.0% at Lugano stage IV and 80.5% monomorphic PTLD. The mean EBV viral load was 12,198 IU/mL. One- and two-year patient survival post-diagnosis was 60.4% and 46.8%, respectively. In the Cox regression analysis, age at PTLD diagnosis (HR for each year = 1.039; p < 0.001) and EBV viral load (HR for each log = 1.695; p = 0.026) were associated with risk of death. Conclusion: This study suggests that in patients predominantly on TAC/AZA, PTLD with simultaneous EBV positive viral load is a late event, and worse survival is associated with older age and EBV viral load at diagnosis. Introduction (KTRs posttransplant post (PTLD EpsteinBarr Epstein Barr (EBV Methods 201 2020 Outcome Results 1625 1 625 1,62 PCR 2018–2020 20182020 reason 23 14.6% 146 14 6 (14.6% 4 17.2% 172 17 2 (17.2% 401 40 40. 86 8 8. transplantation 268 26 26.8 927 92 7 92.7 TAC/AZA TACAZA TAC AZA (TAC/AZA regimen 75.6% 756 75 (75.6% 48.8%, 488 48.8% , 48 (48.8%) 610 61 0 61.0 805 80 5 80.5 12198 12 198 12,19 IUmL IU mL IU/mL One twoyear postdiagnosis 604 60 60.4 468 46 46.8% respectively analysis HR 1.039 1039 039 0.001 0001 001 1.695 1695 695 0.026 0026 026 Conclusion event 20 202 162 62 1,6 2018–202 2018202 14.6 (14.6 17.2 (17.2 26. 9 92. 75.6 (75.6 48.8 (48.8% 61. 80. 1219 19 12,1 60. 46.8 1.03 103 03 0.00 000 00 1.69 169 69 0.02 002 02 16 1, 2018–20 201820 14. (14. 17. (17. 75. (75. 48. (48.8 121 12, 46. 1.0 10 0.0 1.6 2018–2 20182 (14 (17 (75 (48. 1. 0. 2018– (1 (7 (48 ( (4

Resumo Introdução: Este estudo investigou variáveis associadas à mortalidade em receptores de transplante renal (RTR) diagnosticados com doença linfoproliferativa pós-transplante (PTLD, do inglês post-transplant lymphoproliferative disease) e viremia simultânea pelo vírus Epstein-Barr (EBV). Métodos: Estudo de coorte retrospectivo incluindo RTR diagnosticados com PTLD entre 2018 e 2020. Desfecho: óbito em até dois anos após diagnóstico. Resultados: Entre 1.625 RTR que realizaram coleta de viremia para EBV (por PCR, 2018–2020) por qualquer motivo, 238 (14,6%) apresentaram carga viral positiva e 41 (17,2%) PTLD simultânea. Esses 41 pacientes tinham em média 40,1 anos ao diagnóstico e 8,6 anos após o transplante; 26,8% foram induzidos com rATG e 92,7% foram mantidos com tacrolimus e azatioprina (TAC/AZA) como regime imunossupressor. Linfonodos (75,6%) foram o local mais comum de PTLD, seguidos pelo trato gastrointestinal (48,8%), com 61,0% no estágio IV de Lugano e 80,5% PTLD monomórfica. A carga viral média do EBV foi 12.198 UI/mL. A sobrevida dos pacientes em um e dois anos após o diagnóstico foi 60,4% e 46,8%, respectivamente. Na análise de regressão de Cox, a idade ao diagnóstico de PTLD (HR para cada ano = 1,039; p < 0,001) e a carga viral do EBV (HR para cada log = 1,695; p = 0,026) foram associadas ao risco de óbito. Conclusão: Este estudo sugere que, em pacientes predominantemente em uso de TAC/AZA, a PTLD com carga viral simultânea positiva para EBV é um evento tardio, e a pior sobrevida está associada à idade mais avançada e à carga viral de EBV no momento do diagnóstico. Introdução (RTR póstransplante pós (PTLD posttransplant post transplant disease EpsteinBarr Epstein Barr EBV. . (EBV) Métodos 201 2020 Desfecho Resultados 1625 1 625 1.62 PCR 2018–2020 20182020 motivo 23 14,6% 146 14 6 (14,6% 4 17,2% 172 17 2 (17,2% 401 40 40, 86 8 8, 268 26 26,8 927 92 7 92,7 TAC/AZA TACAZA TAC AZA (TAC/AZA imunossupressor 75,6% 756 75 (75,6% 48,8%, 488 48,8% , 48 (48,8%) 610 61 0 61,0 805 80 5 80,5 monomórfica 12198 12 198 12.19 UImL UI mL UI/mL 604 60 60,4 468 46 46,8% respectivamente Cox HR 1,039 1039 039 0,001 0001 001 1,695 1695 695 0,026 0026 026 Conclusão tardio (EBV 20 202 162 62 1.6 2018–202 2018202 14,6 (14,6 17,2 (17,2 26, 9 92, 75,6 (75,6 48,8 (48,8% 61, 80, 1219 19 12.1 60, 46,8 1,03 103 03 0,00 000 00 1,69 169 69 0,02 002 02 16 1. 2018–20 201820 14, (14, 17, (17, 75, (75, 48, (48,8 121 12. 46, 1,0 10 0,0 1,6 2018–2 20182 (14 (17 (75 (48, 1, 0, 2018– (1 (7 (48 ( (4

Abstract Introduction: In December 2016, an outbreak of sylvatic yellow fever (YF) occurred in the non-endemic areas of the south-eastern region of Brazil. The immune response to the yellow fever vaccine and its safety in individuals with chronic kidney disease (CKD) living in YF-endemic regions are not thoroughly understood. The objective of this study is to assess the incidence of adverse events and the serological response after primary vaccination with the 17DD-YF vaccine in CKD patients undergoing dialysis. Methods: This was a multicenter, retrospective cohort study involving 223 individuals with CKD who were on dialysis after primary vaccination against YF. Clinical and epidemiologic characteristics were collected and the vaccine adverse event (VAE) were assessed. Around 35 months after vaccination, the serological response was evaluated in 71 (32%) patients using neutralization tests. Results: No serious VAE occurred in any patient. Local reactions were reported in 13 individuals (5.8%), while 6 (2.7%) reported generalized systemic reactions and 205 (91.9%) did not display any VAE. No clinical or epidemiologic characteristic predicted the occurrence of VAE. Adequate serological response was found in 38% of participants and none of the clinical or epidemiological characteristics were associated with immunogenicity. Conclusion: The outcomes of our study suggest that the yellow YF vaccine is well-tolerated in CKD patients undergoing dialysis, but it does not induce adequate immune response. Future research should focus on evaluating both cellular and humoral immune responses following administration of various doses of the YF vaccine. Introduction 2016 (YF nonendemic non endemic southeastern south eastern Brazil (CKD YFendemic understood 17DDYF DDYF 17DD DD Methods multicenter 22 (VAE assessed 3 7 32% 32 (32% tests Results patient 1 5.8%, 58 5.8% , 5 8 (5.8%) 2.7% 27 2 (2.7% 20 91.9% 919 91 9 (91.9% 38 immunogenicity Conclusion welltolerated well tolerated 201 (32 5.8 (5.8% 2.7 (2.7 91.9 (91.9 (3 5. (5.8 2. (2. 91. (91. ( (5. (2 (91 (5 (9

Resumo Introdução: Em dezembro de 2016, houve um surto de febre amarela (FA) silvestre em áreas não endêmicas da região sudeste do Brasil. A resposta imunológica à vacina contra FA e sua segurança em indivíduos com doença renal crônica (DRC) que vivem em regiões endêmicas de febre amarela não são totalmente compreendidas. O objetivo deste estudo foi avaliar a incidência de eventos adversos e a resposta sorológica após vacinação primária com a vacina 17DD-YF em pacientes com DRC submetidos à diálise. Métodos: Este foi um estudo de coorte retrospectivo e multicêntrico envolvendo 223 indivíduos com DRC que estavam em diálise após vacinação primária contra FA. Foram coletadas características clínicas, epidemiológicas e avaliados os eventos adversos da vacina (EAV). Cerca de 35 meses após a vacinação, a resposta sorológica foi avaliada em 71 (32%) pacientes usando testes de neutralização. Resultados: Não houve EAV grave em nenhum paciente. Reações locais foram relatadas em 13 indivíduos (5,8%), enquanto 6 (2,7%) relataram reações sistêmicas generalizadas e 205 (91,9%) não apresentaram nenhum EAV. Nenhuma característica clínica ou epidemiológica predisse a ocorrência de EAV. Uma resposta sorológica adequada foi encontrada em 38% dos participantes e nenhuma das características clínicas ou epidemiológicas foi associada à imunogenicidade. Conclusão: Os desfechos de nosso estudo sugerem que a vacina contra FA é bem tolerada em pacientes com DRC em diálise, mas não induz uma resposta imunológica adequada. Pesquisas futuras devem se concentrar na avaliação das respostas imunes tanto celulares quanto humorais após a administração de várias doses da vacina contra FA. Introdução 2016 (FA Brasil (DRC compreendidas 17DDYF DDYF 17DD YF DD Métodos 22 . (EAV) 3 7 32% 32 (32% neutralização Resultados paciente 1 5,8%, 58 5,8% , 5 8 (5,8%) 2,7% 27 2 (2,7% 20 91,9% 919 91 9 (91,9% 38 imunogenicidade Conclusão 201 (EAV (32 5,8 (5,8% 2,7 (2,7 91,9 (91,9 (3 5, (5,8 2, (2, 91, (91, ( (5, (2 (91 (5 (9

Introduction: Patients with end-stage renal disease (ESRD) frequently change renal replacement (RRT) therapy modality due to medical or social reasons. We aimed to evaluate the outcomes of patients under peritoneal dialysis (PD) according to the preceding RRT modality. Methods: We conducted a retrospective observational single-center study in prevalent PD patients from January 1, 2010, to December 31, 2017, who were followed for 60 months or until they dropped out of PD. Patients were divided into three groups according to the preceding RRT: prior hemodialysis (HD), failed kidney transplant (KT), and PD-first. Results: Among 152 patients, 115 were PD-first, 22 transitioned from HD, and 15 from a failing KT. There was a tendency for ultrafiltration failure to occur more in patients transitioning from HD (27.3% vs. 9.6% vs. 6.7%, p = 0.07). Residual renal function was better preserved in the group with no prior RRT (p < 0.001). A tendency towards a higher annual rate of peritonitis was observed in the prior KT group (0.70 peritonitis/year per patient vs. 0.10 vs. 0.21, p = 0.065). Thirteen patients (8.6%) had a major cardiovascular event, 5 of those had been transferred from a failing KT (p = 0.004). There were no differences between PD-first, prior KT, and prior HD in terms of death and technique survival (p = 0.195 and p = 0.917, respectively) and PD efficacy was adequate in all groups. Conclusions: PD is a suitable option for ESRD patients regardless of the previous RRT and should be offered to patients according to their clinical and social status and preferences. Introduction endstage end stage (ESRD (RRT reasons (PD Methods singlecenter single center 1 2010 31 2017 6 , (HD) (KT) PDfirst. PDfirst first. first PD-first Results 11 PDfirst, first, 2 27.3% 273 27 3 (27.3 vs 96 9 9.6 67 7 6.7% 0.07. 007 0.07 . 0 07 0.07) 0.001. 0001 0.001 001 0.001) 0.70 070 70 (0.7 peritonitisyear year 010 10 0.1 021 21 0.21 0.065. 0065 0.065 065 0.065) 8.6% 86 8 (8.6% event 0.004. 0004 0.004 004 0.004) 0195 195 0.19 0917 917 0.917 respectively Conclusions preferences 201 (HD (KT 27.3 (27. 9. 6.7 00 0.0 000 0.00 0.7 (0. 01 0. 02 0.2 006 0.06 06 8.6 (8.6 019 19 091 91 0.91 20 27. (27 6. (0 8. (8. 09 0.9 (2 ( (8

Introdução: Pacientes com doença renal em estágio terminal (DRET) frequentemente mudam de modalidade de terapia renal substitutiva (TRS) por razões médicas ou sociais. Nosso objetivo foi avaliar desfechos de pacientes em diálise peritoneal (DP) segundo a modalidade anterior de TRS. Métodos: Realizamos estudo retrospectivo observacional unicêntrico, em pacientes prevalentes em DP, de 1º de janeiro de 2010 a 31 de dezembro de 2017, acompanhados por 60 meses ou até saírem de DP. Pacientes foram divididos em três grupos de acordo com a TRS anterior: hemodiálise prévia (HD), transplante renal malsucedido (TR) e DP como primeira opção (PD-first). Resultados: Entre 152 pacientes, 115 eram PD-first, 22 transitaram da HD e 15 de TR malsucedido. Houve tendência à maior ocorrência de falência de ultrafiltração em pacientes em transição da HD (27,3% vs. 9,6% vs. 6,7%; p = 0,07). A função renal residual foi melhor preservada no grupo sem TRS prévia (p < 0,001). Observou-se tendência à maior taxa anual de peritonite no grupo TR prévio (0,70 peritonite/ano por paciente vs. 0,10 vs. 0,21; p = 0,065). Treze pacientes (8,6%) tiveram um evento cardiovascular maior, cinco dos quais haviam sido transferidos de um TR malsucedido (p = 0,004). Não houve diferenças entre PD-first, TR prévio e HD prévia em termos de óbito e sobrevida da técnica (p = 0,195 e p = 0,917, respectivamente) e a eficácia da DP foi adequada em todos os grupos. Conclusões: A DP é uma opção adequada para pacientes com DRET, independentemente da TRS anterior, e deve ser oferecida aos pacientes de acordo com seu status clínico e social e suas preferências. Introdução DRET (DRET (TRS sociais (DP Métodos unicêntrico º 201 3 2017 6 HD, , (HD) (TR PDfirst. PDfirst PD first . (PD-first) Resultados 11 PDfirst, first, PD-first 2 1 27,3% 273 27 (27,3 vs 96 9 9,6 6,7% 67 7 0,07. 007 0,07 0 07 0,07) 0,001. 0001 0,001 001 0,001) Observouse Observou se 0,70 070 70 (0,7 peritoniteano ano 010 10 0,1 0,21 021 21 0,065. 0065 0,065 065 0,065) 8,6% 86 8 (8,6% 0,004. 0004 0,004 004 0,004) 0195 195 0,19 0917 917 0,917 respectivamente Conclusões preferências 20 (HD (PD-first 27,3 (27, 9, 6,7 00 0,0 000 0,00 0,7 (0, 01 0, 0,2 02 006 0,06 06 8,6 (8,6 019 19 091 91 0,91 27, (27 6, (0 8, (8, 09 0,9 (2 ( (8

Resumo Historicamente, são necessários, em média, 17 anos para que novos tratamentos passem da evidência clínica para a prática diária. Considerando os tratamentos altamente eficazes disponíveis atualmente para prevenir ou retardar o início e a progressão da doença renal, esse período é demasiadamente longo. Agora é o momento de reduzir a lacuna entre o que sabemos e aquilo que fazemos. Existem diretrizes claras para a prevenção e o manejo dos fatores de risco comuns para doenças renais, como hipertensão e diabetes, mas apenas uma fração das pessoas com essas condições é diagnosticada mundialmente, e um número ainda menor recebe tratamento adequado. Da mesma forma, a grande maioria das pessoas que sofrem de doença renal não têm conhecimento de sua condição, pois ela costuma ser silenciosa nos estágios iniciais. Mesmo entre pacientes que foram diagnosticados, muitos não recebem tratamento adequado para a doença renal. Levando em consideração as graves consequências da progressão da doença renal, insuficiência renal ou óbito, é imperativo que os tratamentos sejam iniciados precocemente e de maneira adequada. As oportunidades para diagnosticar e tratar precocemente a doença renal devem ser maximizadas, começando no nível da atenção primária. Existem muitas barreiras sistemáticas, que vão desde o paciente até o médico, passando pelos sistemas de saúde e por fatores sociais. Para preservar e melhorar a saúde renal para todos em qualquer lugar, cada uma dessas barreiras deve ser reconhecida para que soluções sustentáveis sejam desenvolvidas e implementadas sem mais demora. Historicamente necessários média 1 diária longo fazemos renais diabetes mundialmente forma condição iniciais diagnosticados óbito adequada maximizadas primária sistemáticas médico sociais lugar demora

Abstract Historically, it takes an average of 17 years for new treatments to move from clinical evidence to daily practice. Given the highly effective treatments now available to prevent or delay kidney disease onset and progression, this is far too long. Now is the time to narrow the gap between what we know and what we do. Clear guidelines exist for the prevention and management of common risk factors for kidney disease, such as hypertension and diabetes, but only a fraction of people with these conditions are diagnosed worldwide, and even fewer are treated to target. Similarly, the vast majority of people living with kidney disease are unaware of their condition, because it is often silent in the early stages. Even among patients who have been diagnosed, many do not receive appropriate treatment for kidney disease. Considering the serious consequences of kidney disease progression, kidney failure, or death, it is imperative that treatments are initiated early and appropriately. Opportunities to diagnose and treat kidney disease early must be maximized beginning at the primary care level. Many systematic barriers exist, ranging from the patient to the clinician to the health systems to societal factors. To preserve and improve kidney health for everyone everywhere, each of these barriers must be acknowledged so that sustainable solutions are developed and implemented without further delay. Historically 1 practice progression long diabetes worldwide target Similarly condition stages failure death appropriately level everywhere

Resumen El sarcoma de Ewing (ES) y el tumor neuroectodérmi co primitivo (PNET) pertenecen al grupo de neoplasias denominadas tumores de células pequeñas y redondas. Los PNET se dividen en centrales y periféricos. El ES y los PNET periféricos surgen del tejido óseo, de los tejidos blandos o nervios periféricos. Presentamos un caso de ES/PNET hepático en un hombre sano que inició cuatro meses antes de la consulta con síntomas abdominales y pérdida de peso. La endoscopia digestiva alta y la analí tica no revelaron hallazgos relevantes. En la tomografía de abdomen se evidenció hígado aumentado de tamaño a expensas de lesión sólida que comprometía todos sus segmentos con realce al contraste endovenoso y grandes áreas de necrosis. Comprimía y desplazaba estructuras vecinas. Se realizó biopsia con aguja gruesa de la lesión hepática: neoplasia de células pequeñas y redondas. La inmunohistoquímica reveló negatividad para CD45, CKA1/A3, cromogranina, sinaptofisina y citoqueratinas CK7 y CK20. Expresión tenue de CD56 y positividad de CD99, FLI-1 y NKX2. Realizó tratamiento quimioterápico con carboplatino y etopósido por 6 ciclos con mejoría clínica y tolerancia al mismo. En imágenes de control se evidenció reducción de la masa con afección del lóbulo hepático derecho, compromiso de la vena cava inferior, infiltración de la glándula suprarrenal y polo superior del riñón derechos. Se remitió a cirugía hepatobiliar para resección quirúrgica de la lesión residual. El paciente rechazó el procedimiento quirúrgico. Nuestro objetivo es destacar el desafío diagnóstico clínico e histológico de esta entidad que obliga a descartar otras entidades clínicas.

Abstract Ewing sarcoma (ES) and primitive neuroectodermal tumor (PNET) belong to the group of neoplasms called small round cell tumors. PNETs have been divided into central and peripheral. ES and peripheral PNETs arise from bones, soft tissues, or peripheral nerves. We pres ent a case of hepatic ES/PNET in a healthy man that began four months before consultation with abdominal symptoms and weight loss. Upper gastrointestinal en doscopy and laboratory tests revealed no notable find ings. The abdominal tomography revealed an enlarged liver due to a solid lesion that involved all its segments with intravenous contrast enhancement and large areas of necrosis. It compressed and displaced neighboring structures. Core needle biopsy of the liver lesion was per formed: small round cell neoplasm. Immunohistochemis try revealed negativity for CD45, CKA1/A3, chromogranin, synaptophysin, and cytokeratins CK7 and CK20. Dim CD56 expression and CD99, FLI-1, and NKX2 positivity. He underwent chemotherapy treatment with carboplatin and etoposide for 6 cycles with clinical improvement and tolerance. Control images showed reduction of the mass with involvement of the right hepatic lobe, involvement of the inferior vena cava, infiltration of the right adrenal gland and upper pole of the right kidney. He was referred to hepatobiliary surgery for surgical resection of the residual lesion. The patient rejected the proposed surgi cal procedure. Our objective is to highlight the clinical and histological diagnostic challenge of this entity that requires ruling out other clinical entities.

Resumen Presentamos un paciente con una rara enfermedad autoinflamatoria sistémica (deficiencia de mevalonato quinasa -DMQ-) con la identificación de dos variantes heterocigotas (c.1129G>A y c.32C>T) en el gen Meval onato Quinasa, detectadas por secuenciación masiva en paralelo y una glomerulonefritis de alta prevalencia (nefropatía por IgA). El paciente presentó un cuadro de fiebre periódica recurrente mensual desde los 12 días de vida, acompañada de lesiones mucocutáneas (rash maculopapular en extremidades, estomatitis aftosa), compromiso articular (artralgias en tobillos, muñecas y rodillas), linfoideo (linfoadenopatía cervical, esplenome galia), gastrointestinal (diarrea, dolor abdominal) y renal (hematuria y proteinuria) con repetidas biospias most rando nefropatía por IgA alternando actividad y cronic idad. Durante el seguimiento, tuvo una pobre respuesta terapéutica a múltiples esquemas inmunosupresores utilizados durante 7 años (corticoides, azatrioprina, micofenolato, ciclofosfamida, rituximab y tocilizumab), y buena respuesta finalmente a canakinumab. Cuatro años posteriores al inicio de canakinumab, durante el curso de una infección por un absceso muscular, el cuadro clínico se complica con un evento microvascular renal grave (necrosis cortical renal -NCR-) con fallo renal agudo y necesidad de diálisis. Los episodios recurrentes de inflamación por la DMQ podrían actuar como gatil los para la reactivación de su glomerulonefritis (lo que explicaría la escasa respuesta a inmunosupresores y la progresión rápida a cronicidad histológica) y para gen erar un microambiente que predisponga el desarrollo de una NCR ante una infección no grave. En la DMQ se ha descripto un defecto en las moléculas de IgA, fenómeno también observado en la nefropatía por IgA. Esto plantea la desafiante hipótesis de un vínculo patogénico común entre todas las manifestaciones clínicas del paciente.

Abstract We present a patient with a rare systemic autoinflam matory disease (mevalonate kinase deficiency -MKD-) with the identification of two heterozygous variants (c.1129G>A and c.32C>T) in the Mevalonate Kinase gene, detected by next generation sequencing and a highly prevalent glomerulonephritis (IgA nephropathy). The patient presents clinically with a monthly recurrent periodic fever from 12 days of age, accompanied by mucocutaneous lesions (maculopapular rash in ex tremities, aphthous stomatitis), joint (arthralgias in ankles, wrists and knees), lymphoid (cervical lymph adenopathy, splenomegaly), gastrointestinal (diarrhea, abdominal pain) and kidney (hematuria and protei-nuria) with repeated biopsies showing IgA nephropathy alternating activity with chronicity. During follow-up. The patients presented a poor therapeutic response to multiple immunosuppressive regimens used for 7 years (corticosteroids, azathioprine, mycophenolate, cyclo phosphamide, rituximab and tocilizumab), and finally a good response to canakinumab. Four years after starting canakinumab, during the course of an infection due to a muscle abscess, the clinical presentation is complicated by a severe renal microvascular event (renal cortical necrosis -RCN-) with acute kidney injury and dialysis requirement. Therecurrent episodes of inflammation due to MKD could act as triggers for the reactivation of glomerulonephritis (which would explain the poor response to immunosuppressants and the rapid pro gression to histological chronicity) and to generate a microenvironment that predisposes the development of RCN in the face of a non-serious infection. A defect in IgA molecules has been described in MKD, a phenom enon also observed in IgA nephropathy. This raises the challenging hypothesis of a common pathogenetic link between all the patient’s clinical manifestations.

ABSTRACT Introduction: Chronic kidney disease is a global health problem. Its most serious manifestation, chronic kidney failure, affects the Cuban context and determines the growth of patients on hemodialysis. The objective of the text is to evaluate the main results of the diagnosis and characterization of the problematic situation in a psychosocial study with patients with Chronic Renal Failure in the Hemodialysis room of the Florida municipality, of the county of Camagüey. Method: It is an experimental participatory action research, which takes place between January 2023 and December 2024, which constitutes the output of the research project System of psychosocial actions for the improvement of comprehensive care for patients with non-communicable diseases. The universe is made up of 56 patients and the sample is made up of 22, who receive purifying and conservative treatment, 22 family members and 12 service professionals. The research instrument par excellence was the participant survey. Results: The age of the patients is not definitive of an age group; men predominate; A high percentage of patients are found to have low tolerance for adherence to treatment and insufficient development of psychosocial skills and declare the need to possess knowledge to achieve health states that lead to survival. Discussion: There is no coincidence with what was found in the determination of the prevalence age groups for the disease, but specialists insist that the disease is not exclusive to a specific period of life; recognize the importance of the patient's knowledge of risk factors for prevention, promotion and health education and highlight the need for communication and empathy between health personnel and the patient, to achieve favorable results and emotional states in the face of the disease and treatment.

RESUMEN Introducción: La enfermedad renal crónica es un problema de salud a nivel mundial, su manifestación más grave, la insuficiencia renal crónica, incide en el contexto cubano y determina el crecimiento de pacientes en hemodiálisis. El objetivo del texto es valorar los principales resultados del diagnóstico y caracterización de la situación problémica en un estudio de carácter psicosocial con pacientes con Insuficiencia Renal Crónica en la sala de Hemodiálisis del municipio Florida, de la provincia de Camagüey. Método: Es una investigación-acción participativa de corte experimental, que se desarrolla entre enero 2023 y diciembre del 2024 la cual constituye salida del proyecto de investigación Sistema de acciones psicosociales para el perfeccionamiento de la atención integral a los pacientes con enfermedades no transmisibles. El universo está constituido por 56 pacientes y la muestra por 22, que reciben tratamiento depurador y conservador, 22 familiares y 12 profesionales del servicio. El instrumento de investigación por excelencia fue la encuesta a participantes. Resultados: La edad de los pacientes no es definitiva de un grupo etario; predominan los hombres; se constata un elevado por ciento de pacientes con poca tolerancia a la adherencia al tratamiento e insuficiente desarrollo de las habilidades psicosociales y declaran la necesidad de poseer conocimientos para lograr estados de salud que conlleven a la sobrevida. Discusión: No existe coincidencia con lo constatado en la determinación de los grupos etarios de prevalencia para la enfermedad, pero los especialistas insisten en que la enfermedad no es privativa de un período de vida específico; reconocen la importancia del conocimiento de los factores de riesgo por el paciente para la prevención, promoción y educación en salud y resaltan la necesidad de la comunicación y la empatía entre el personal de salud y el paciente, para lograr resultados y estados emocionales favorables ante la enfermedad y el tratamiento.

Abstract Background Chagas disease (CD) is a serious public health problem in Latin America. Benznidazole (BNZ) is used for the treatment of CD and, despite its wide use, little information is available about its toxicity and mechanisms of adverse drug reactions (ADR). Objectives To identify and classify clinical and laboratory adverse reactions caused by BNZ in terms of causality and severity. Methods Prospective cohort study from January 2018 to December 2021. Treatment follow-up included visits and biochemical tests (complete blood count, liver and kidney function tests) before, during and after treatment. ADR were classified according to causality and severity. In the statistical analysis, the significance level was set at p<0.05. Results Forty patients with chronic CD were included. A high prevalence of ADR was observed 161 ADR in 30 patients [90%]; of these, 104 (64.6%) were classified as possible and 57 (35.4%) as probable. The ADR were classified as moderate and mild. Of the 40 patients, nine (22.5%) discontinued treatment. ADR associated with treatment discontinuation and interventions were those that affected the dermatological system, central and peripheral nervous system and sense organs such as ageusia. Mild hematological and biochemical changes such as lymphopenia were observed after 30 days of treatment. Conclusion Many patients were able to complete the treatment even with ADR, which can be attributed to the successful follow-up strategy with symptomatic treatment and counseling, leading to patient’s awareness of symptoms and treatment adherence. (CD America (BNZ use ADR. . (ADR) severity 201 2021 followup follow up count before analysis p005 p 0 05 p<0.05 16 3 90% 90 [90%] these 10 64.6% 646 64 6 (64.6% 5 35.4% 354 35 4 (35.4% probable mild 22.5% 225 22 (22.5% ageusia counseling patient s adherence (ADR 20 202 p00 p<0.0 1 9 [90% 64.6 (64.6 35.4 (35.4 22.5 2 (22.5 p0 p<0. [90 64. (64. 35. (35. 22. (22. p<0 [9 (64 (35 (22 p< [ (6 (3 (2 (

Resumo Fundamento A Doença de Chagas (DC) representa um grave problema de saúde pública na América Latina. O Benznidazol (BNZ) é utilizado para o tratamento DC e, apesar do seu amplo uso, poucas informações estão disponíveis sobre sua toxicidade e mecanismos das Reações Adversas ao Medicamento (RAM). Objetivos Identificar e classificar as reações adversas clínicas e laboratoriais ocasionadas pelo uso do BNZ quanto à sua causalidade e gravidade. Métodos Estudo de coorte prospectivo realizado no período de janeiro de 2018 a dezembro de 2021. O acompanhamento do tratamento incluiu consultas e análises laboratoriais antes, 30 e 60 dias após o início do tratamento. As RAM foram classificadas quanto à causalidade e gravidade. Na análise estatística o nível de significância adotado foi p<0,05. Resultados Participaram do estudo 40 pacientes com DC crônica, observou-se alta prevalência de RAM com um total de 161 em 30 (90%) pacientes. Destas, 104 (64,6%) foram classificadas como possíveis e 57 (35,4%) como prováveis. As reações foram classificadas em moderadas e leves. Dos 40 pacientes, nove (22,5%) suspenderam o tratamento. As RAM associadas à interrupção e intervenções foram as que afetaram o sistema dermatológico, sistema nervoso central e periférico ou que culminaram em ageusia. Após 30 dias de tratamento, alterações hematológicas e bioquímicas leves foram observadas como linfopenia. Conclusão Apesar do elevado percentual de RAM, muitos pacientes foram capazes de completar o tratamento, o que se atribui ao êxito da estratégia de acompanhamento com intervenções de tratamento sintomático juntamente ao aconselhamento, levando à compreensão da sintomatologia e manutenção do tratamento. (DC Latina (BNZ RAM. . (RAM) gravidade 201 2021 antes 3 6 p005 p 0 05 p<0,05 4 crônica observouse observou 16 90% 90 (90% Destas 10 64,6% 646 64 (64,6% 5 35,4% 354 35 (35,4% prováveis 22,5% 225 22 (22,5% dermatológico ageusia linfopenia aconselhamento (RAM 20 202 p00 p<0,0 1 9 (90 64,6 (64,6 35,4 (35,4 22,5 2 (22,5 p0 p<0, (9 64, (64, 35, (35, 22, (22, p<0 ( (64 (35 (22 p< (6 (3 (2

Abstract Introduction: Porphyrias are enzymatic disorders of heme synthesis. Acute hepatic porphyrias (AHP) presents with acute neurovisceral symptoms such as abdominal pain, nausea, vomiting, constipation, muscle weakness, neuropathy, tachycardia, and hypertension. 5-aminolevulinic acid dehydratase (ALAD) deficiency is a rare autosomal recessive disorder that results in little or no elevation of porphobilinogen but elevates urinary 5-aminolevulinic acid and coproporphyrin III. There are no records of this type of porphyria in Colombia. Acute management requires comprehensive care, ranging from hemotherapy to liver transplantation. Case Presentation: A 24-year-old man with no prior medical history presented with a recurrent and acute episode of abdominal pain associated with changes in urine color, skin lesions, diarrhea, and dysregulation of body temperature. Initial paraclinical workup ruled out common causes of recurrent abdominal pain, with a negative porphobilinogen test, but further testing revealed elevated 5-aminolevulinic acid, confirming the diagnosis of ALAD porphyria. The patient showed improvement with hemotherapy and remission of acute kidney injury. A possible distractor associated with interstitial nephritis and skin manifestations related to nonsteroidal anti-inflammatory drug (NSAID) use was documented. Conclusions: ALAD porphyria and all acute hepatic porphyrias should be considered in any patient presenting with unexplained recurrent severe abdominal pain and neuropathy. Despite their relative rarity and complexity, most porphyrias can be easily defined and diagnosed. A common cause of diagnostic delay is the failure to consider porphyria in the differential diagnosis on time. There is still much to learn about ALAD porphyria.

Resumen Introducción: Las porfirias son trastornos enzimáticos de la síntesis del hemo. Las porfirias hepáticas agudas (PHA) se presentan con síntomas neuroviscerales agudos, como dolor abdominal, náuseas, vómitos, estreñimiento, debilidad muscular, neuropatía, taquicardia e hipertensión. La deficiencia de ácido 5-aminolevulínico deshidratasa (ALAD) es un trastorno autosómico recesivo raro que provoca poca o ninguna elevación de porfobilinógeno, pero eleva el ácido 5-aminolevulínico y la coproporfirina III urinaria. No hay registros de este tipo de porfiria en Colombia. En la fase aguda requiere manejo integral, desde hemoterapia hasta trasplante hepático. Presentación del caso: Hombre de 24 años sin antecedentes que cursaba con un cuadro recurrente y agudizado de dolor abdominal asociado a cambios en la coloración en la orina, lesiones cutáneas, deposiciones diarreicas y distermias. Dentro de su abordaje con paraclínicos previos se descartaron causas de dolor abdominal recurrente iniciales, con porfobilinógeno negativo, y se completó el estudio con 5-aminolevulínico elevado, lo que configuró la clínica de porfiria por ALAD, con mejoría ante la hemoterapia y remisión de lesión renal aguda. Se documentó el distractor asociado posible de nefritis intersticial y manifestaciones en la piel derivadas del consumo de antiinflamatorios no esteroideos (AINE). Conclusiones: Se debe considerar la porfiria por ALAD y todas las porfirias hepáticas agudas en cualquier paciente que presente recurrencia inexplicable de dolor abdominal grave y neuropatía. A pesar de su relativa rareza y complejidad, la mayoría de las porfirias se pueden definir y diagnosticar fácilmente. Una de las causas más frecuentes en el retraso diagnóstico radica en no considerar este diagnóstico en los diferenciales de manera oportuna. Aún falta mucho por conocer de la porfiria por ALAD.

ABSTRACT Online hemodiafiltration (HDF) is a rapidly growing dialysis modality worldwide. In Brazil, the number of patients with private health insurance undergoing HDF has exceeded the number of patients on peritoneal dialysis. The achievement of a high convection volume was associated with better clinical imprand patient – reported outcomes confirming the benefits of HDF. The HDFit trial provided relevant practical information on the implementation of online HDF in dialysis centers in Brazil. This article aims to disseminate technical information to improve the quality and safety of this new dialysis modality. (HDF worldwide Brazil

RESUMO A hemodiafiltração (HDF) on-line é uma modalidade dialítica em rápido crescimento no mundo. No Brasil, o número de pacientes com planos de saúde privados tratados por HDF já ultrapassa aquele de pacientes em diálise peritoneal. O alcance de um alto volume convectivo associado à redução de desfechos clínicos e do risco de morte confirmam os benefícios da HDF. Dados nacionais do estudo HDFit forneceram informações práticas relevantes sobre a implementação da HDF on-line em clínicas de diálise no Brasil. O objetivo desta publicação é a disseminação de informações técnicas que possam auxiliar na utilização, com qualidade e segurança, dessa nova modalidade dialítica. (HDF online on line mundo Brasil peritoneal utilização segurança

ABSTRACT The CONVINCE study, recently published in the New England Journal of Medicine, reveals a groundbreaking 23% reduction in the relative risk of all-cause mortality among end-stage kidney patients undergoing high convective volume hemodiafiltration. This significant finding challenges the conventional use of high-flux hemodialysis and offers hope for improving outcomes in chronic kidney disease patients. While some controversies surround the study’s findings, including concerns about generalizability and the causes of death, it is essential to acknowledge the study’s design and its main outcomes. The CONVINCE study, part of the HORIZON 2020 project, enrolled 1360 patients and demonstrated the superiority of hemodiafiltration in reducing all-cause mortality overall, as well as in specific patient subgroups (elderly, short vintage, non-diabetic, and those without cardiac issues). Interestingly, it was shown that hemodiafiltration had a protective effect against infection, including COVID-19. Future research will address sustainability, dose scaling effects, identification of subgroups especially likely to benefit and cost-effectiveness. However, for now, the findings strongly support a broader adoption of hemodiafiltration in renal replacement therapy, marking a significant advancement in the field. study Medicine 23 allcause all cause endstage end stage highflux flux studys s death 202 project 136 overall elderly, elderly (elderly vintage nondiabetic, nondiabetic non diabetic, diabetic non-diabetic issues. issues . issues) Interestingly infection COVID19. COVID19 COVID 19. 19 COVID-19 sustainability effects costeffectiveness. costeffectiveness cost effectiveness. effectiveness cost-effectiveness However now therapy field 2 20 13 COVID1 1 COVID-1 COVID-

RESUMO O estudo CONVINCE, publicado recentemente no New England Journal of Medicine, revela uma redução inovadora de 23% no risco relativo de mortalidade por todas as causas entre pacientes renais em estágio terminal submetidos à hemodiafiltração de alto volume de convecção. Esse achado significativo desafia o uso convencional da hemodiálise de alto fluxo e oferece esperança de melhoria dos desfechos em pacientes com doença renal crônica. Embora algumas controvérsias cerquem os achados do estudo, incluindo preocupações sobre a generalização e as causas de óbito, é essencial reconhecer o desenho do estudo e seus principais desfechos. O estudo CONVINCE, parte do projeto HORIZON 2020, inscreveu 1.360 pacientes e demonstrou a superioridade da hemodiafiltração na redução da mortalidade por todas as causas em geral, bem como em subgrupos específicos de pacientes (idosos, HD de curta duração, não diabéticos e aqueles sem problemas cardíacos). Curiosamente, demonstrou-se que a hemodiafiltração teve um efeito protetor contra infecções, incluindo a COVID-19. Pesquisas futuras abordarão sustentabilidade, efeitos de escalonamento da dose, identificação de subgrupos especialmente propensos a se beneficiar e a relação custo-benefício. No entanto, por ora, os achados apoiam fortemente uma adoção mais ampla da hemodiafiltração na terapia renal substitutiva, marcando um avanço significativo na área. CONVINCE Medicine 23 convecção crônica óbito 2020 1360 1 360 1.36 geral idosos, idosos (idosos duração cardíacos. cardíacos . cardíacos) Curiosamente demonstrouse infecções COVID19. COVID19 COVID 19. 19 COVID-19 sustentabilidade dose custobenefício. custobenefício custo benefício. benefício custo-benefício entanto ora substitutiva área 2 202 136 36 1.3 COVID1 COVID-1 20 13 3 1. COVID-

Abstract Background: Kidney transplantation (KT) improves quality of life, including fertility recovery. Objective: to describe outcomes of post-KT pregnancy and long-term patient and graft survival compared to a matched control group of female KT recipients who did not conceive. Methods: retrospective single-center case-control study with female KT recipients from 1977 to 2016, followed-up until 2019. Results: there were 1,253 female KT patients of childbearing age in the study period: 78 (6.2%) pregnant women (cases), with a total of 97 gestations. The median time from KT to conception was 53.0 (21.5 – 91.0) months. Abortion rate was 41% (spontaneous 21.6%, therapeutic 19.6%), preterm delivery, 32%, and at term delivery, 24%. Pre-eclampsia (PE) occurred in 42% of pregnancies that reached at least 20 weeks. The presence of 2 or more risk factors for poor pregnancy outcomes was significantly associated with abortions [OR 3.33 (95%CI 1.43 – 7.75), p = 0.007] and with kidney graft loss in 2 years. The matched control group of 78 female KT patients was comparable on baseline creatinine [1.2 (1.0 – 1.5) mg/dL in both groups, p = 0.95] and urine protein-to-creatinine ratio (UPCR) [0.27 (0.15 – 0.44) vs. 0.24 (0.02 – 0.30), p = 0.06]. Graft survival was higher in cases than in controls in 5 years (85.6% vs 71.5%, p = 0.012) and 10 years (71.9% vs 55.0%, p = 0.012) of follow-up. Conclusion: pregnancy can be successful after KT, but there are high rates of abortions and preterm deliveries. Pre-conception counseling is necessary, and should include ethical aspects. Background (KT life recovery Objective postKT post longterm long conceive Methods singlecenter single center casecontrol case 197 2016 followedup followed up 2019 Results 1253 1 253 1,25 period 7 6.2% 62 6 (6.2% cases, , (cases) 9 gestations 530 53 0 53. 21.5 215 21 (21. 91.0 910 91 months 41 spontaneous 216 21.6% 19.6%, 196 19.6% 19 19.6%) delivery 32 32% 24 24% Preeclampsia Pre eclampsia PE (PE 42 weeks OR 333 3 33 3.3 95%CI 95CI CI 95 143 43 1.4 7.75, 775 7.75 75 7.75) 0.007 0007 007 1.2 12 [1. 1.0 (1. 1.5 15 mgdL mg dL groups 0.95 095 proteintocreatinine protein UPCR (UPCR 0.27 027 27 [0.2 0.15 015 (0.1 0.44 044 44 024 0.2 0.02 002 02 (0.0 0.30, 030 0.30 30 0.30) 0.06. 006 0.06 . 06 0.06] 85.6% 856 85 (85.6 715 71 71.5% 0.012 0012 012 71.9% 719 (71.9 550 55 55.0% followup. followup follow up. follow-up Conclusion deliveries Preconception necessary aspects 201 125 25 1,2 6.2 (6.2 (cases 21. (21 91. 4 21.6 19.6 3. 14 1. 77 7.7 0.00 000 00 [1 (1 0.9 09 [0. 0.1 01 (0. 0.4 04 0. 0.0 03 0.3 85.6 8 (85. 71.5 0.01 001 71.9 (71. 55.0 1, 6. (6. (2 19. 7. [ ( [0 (0 85. (85 71. (71 55. (6 (8 (7

Resumo Histórico: Transplante renal (TR) melhora qualidade de vida, incluindo recuperação da fertilidade. Objetivo: descrever desfechos gestacionais pós-TR e sobrevida de longo prazo da paciente e do enxerto renal comparada a um grupo controle pareado de receptoras de TR que não conceberam. Métodos: estudo retrospectivo caso-controle com receptoras de TR de 1977 a 2016, acompanhadas até 2019. Resultados: foram identificadas 1.253 receptoras de TR em idade fértil no período do estudo: 78 (6,2%) gestantes (casos), total de 97 gestações. Tempo mediano entre TR até concepção foi 53,0 (21,5 – 91,0) meses. Taxa de aborto foi 41% (espontâneo 21,6%, terapêutico 19,6%), parto prematuro, 32%, e a termo, 24%. Pré-eclâmpsia (PE) ocorreu em 42% das gestações que alcançaram pelo menos 20 semanas. Presença de 2 ou mais fatores de risco para desfechos gestacionais desfavoráveis foi significativamente associada a abortos [OR 3,33 (IC95% 1,43 – 7,75), p = 0,007] e perda de enxerto renal em 2 anos. O grupo controle de 78 mulheres com TR foi comparável na creatinina basal [1,2 (1,0 – 1,5) mg/dL nos dois grupos, p = 0,95] e na relação proteína/creatinina urinária (RPCU) [0,27 (0,15 – 0,44) vs. 0,24 (0,02 – 0,30), p = 0,06]. Sobrevida do enxerto foi maior nos casos que nos controles em 5 anos (85,6% vs. 71,5%, p = 0,012) e 10 anos (71,9% vs. 55,0%, p = 0,012) de acompanhamento. Conclusão: a gestação pode ser bem-sucedida após TR, mas existem altas taxas de abortos e partos prematuros. Aconselhamento pré-concepção é necessário e deve incluir aspectos éticos. Histórico (TR vida fertilidade Objetivo pósTR pós conceberam Métodos casocontrole caso 197 2016 2019 Resultados 1253 1 253 1.25 7 6,2% 62 6 (6,2% casos, , (casos) 9 530 53 0 53, 21,5 215 21 (21, 91,0 910 91 meses 41 espontâneo 216 21,6% 19,6%, 196 19,6% 19 19,6%) prematuro 32 32% termo 24 24% Préeclâmpsia Pré eclâmpsia PE (PE 42 semanas OR 333 3 33 3,3 IC95% IC95 IC (IC95 143 43 1,4 7,75, 775 7,75 75 7,75) 0,007 0007 007 1,2 12 [1, 1,0 (1, 1,5 15 mgdL mg dL grupos 0,95 095 95 proteínacreatinina proteína RPCU (RPCU 0,27 027 27 [0,2 0,15 015 (0,1 0,44 044 44 vs 024 0,2 0,02 002 02 (0,0 0,30, 030 0,30 30 0,30) 0,06. 006 0,06 . 06 0,06] 85,6% 856 85 (85,6 715 71 71,5% 0,012 0012 012 71,9% 719 (71,9 550 55 55,0% acompanhamento Conclusão bemsucedida bem sucedida prematuros préconcepção pré éticos 201 125 25 1.2 6,2 (6,2 (casos 21, (21 91, 4 21,6 19,6 3, IC9 (IC9 14 1, 77 7,7 0,00 000 00 [1 (1 0,9 09 [0, 0,1 01 (0, 0,4 04 0, 0,0 03 0,3 85,6 8 (85, 71,5 0,01 001 71,9 (71, 55,0 1. 6, (6, (2 19, (IC 7, [ ( [0 (0 85, (85 71, (71 55, (6 (8 (7